Comments
Cliantha Research has acquired US-based Inflamax Research, a deal that will enable the Ahmedabad-based company to conduct Phase I, II, III and IV research in North America, the company said in a statement.
Inflamax has presences in Toronto, Ontario; Neptune, New Jersey and Newark, New Jersey.
Inflamax’s world-renowned expertise in inflammatory disease research and patented natural allergen Environmental Exposure Chambers (EEC) will allow Cliantha to conduct asthma, allergy, ophthalmology and tobacco research as well as specialised pulmonary/respiratory therapeutic studies, a statement said. “Inflamax is the leader in research in inflammatory disease with a speciality in Environmental Exposure Chamber technologies. Now we can provide our sponsors with advanced clinical trial designs along with a strong, highly experienced scientific team in North America. This acquisition brings us closer to our goal of offering highly specialised trials to our sponsor,” said Vijay Patel, Executive Director, Cliantha Research.
Piyush Patel, CEO of Inflamax Research, said, “This merger brings together the best of our collective scientific research capabilities and expands our infrastructure and offerings to our clients. There are many synergies between Inflamax Research and Cliantha which will offer new and expanded opportunities to our clients.”
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.